Companies: 10,795·Total market cap: $144.5T
aTyr Pharma, Inc.

aTyr Pharma, Inc.

ATYRNASDAQHealthcare● Active
$0.44
$-0.03(-5.94%)
Market Cap$43348436
P/E Ratio
52W High$7.29
52W Low$0.395

aTyr Pharma, Inc. (ATYR) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · ATYR · as of Jun 9, 2026

Activity summary

Buy transactions

3

P-Purchase only

Sell transactions

3

12 Months

Buy/Sell ratio

1.00

Buy/Sell (by trades)

Overall sentiment

NEUTRAL
↑ Buy 50%Active transactions only · RSU vesting excluded50% Sell ↓

aTyr Pharma, Inc. insiders have shown mixed buying and selling activity over the past 12 Months.

Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 9, 2026

ATYR insider buying and selling by quarter

ATYR insider selling · ATYR insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling
2.3M1.2M0
2025 Q2
2025 Q4
2026 Q1
2026 Q2

Mobile shows last 4Q · Desktop shows full 8Q

Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 9, 2026

Active insiders

Most active in past 12 months · ATYR ceo insider trading

Showing all insiders · Click a card to filter the transactions table below

Aggregated from reportingName · top 5 by trade count (12M) · no extra API

Recent insider transactions

ATYR executive sell shares · ATYR board member insider trading · ATYR insider trading SEC filing

Showing 25 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

SCHIMMEL PAUL

Director

Purchase

Date

May 27

Shares

100,000

Price

$0.50

Value

$50K

View Form 4 on SEC.gov

Shukla Sanjay

President and CEO · Director

Option

Date

Feb 3

Shares

10,375

Price

Value

View Form 4 on SEC.gov

Shukla Sanjay

President and CEO · Director

Sale

Date

Feb 4

Shares

3,745

Price

$0.98

Value

$4K

View Form 4 on SEC.gov

Broadfoot Jill Marie

CFO

Option

Date

Feb 3

Shares

3,750

Price

Value

View Form 4 on SEC.gov

Broadfoot Jill Marie

CFO

Sale

Date

Feb 4

Shares

1,558

Price

$0.98

Value

$2K

View Form 4 on SEC.gov

DENYES NANCY

General Counsel

Option

Date

Feb 3

Shares

2,687

Price

Value

View Form 4 on SEC.gov

DENYES NANCY

General Counsel

Sale

Date

Feb 4

Shares

1,118

Price

$0.98

Value

$1K

View Form 4 on SEC.gov

SCHIMMEL PAUL

Director

Purchase

Date

Oct 9

Shares

317,999

Price

$0.94

Value

$299K

View Form 4 on SEC.gov

SCHIMMEL PAUL

Director

Purchase

Date

Oct 8

Shares

682,001

Price

$0.90

Value

$612K

View Form 4 on SEC.gov

Gross Jane A

Director

Purchase

Date

Mar 17

Shares

3,750

Price

$4.00

Value

$15K

View Form 4 on SEC.gov

Shukla Sanjay

President and CEO · Director

Option

Date

Feb 3

Shares

10,375

Price

Value

View Form 4 on SEC.gov

Broadfoot Jill Marie

CFO

Option

Date

Feb 3

Shares

3,750

Price

Value

View Form 4 on SEC.gov

Broadfoot Jill Marie

CFO

Sale

Date

Feb 4

Shares

1,254

Price

$3.78

Value

$5K

View Form 4 on SEC.gov

DENYES NANCY

General Counsel

Option

Date

Feb 3

Shares

2,687

Price

Value

View Form 4 on SEC.gov

DENYES NANCY

General Counsel

Sale

Date

Feb 4

Shares

899

Price

$3.78

Value

$3K

View Form 4 on SEC.gov

SCHIMMEL PAUL

Director

Purchase

Date

Jul 24

Shares

52,300

Price

$1.93

Value

$101K

View Form 4 on SEC.gov

SCHIMMEL PAUL

Director

Purchase

Date

Jul 23

Shares

6,648

Price

$1.82

Value

$12K

View Form 4 on SEC.gov

SCHIMMEL PAUL

Director

Purchase

Date

Jul 22

Shares

41,052

Price

$1.74

Value

$72K

View Form 4 on SEC.gov

DENYES NANCY

General Counsel

Purchase

Date

Jun 5

Shares

5,000

Price

$1.86

Value

$9K

View Form 4 on SEC.gov

EcoR1 Capital Fund Qualified, L.P.

10 percent owner

Purchase

Date

Nov 1

Shares

24,728

Price

$4.80

Value

$119K

View Form 4 on SEC.gov

EcoR1 Capital Fund Qualified, L.P.

10 percent owner

Sale

Date

Nov 8

Shares

1,070

Price

$4.30

Value

$5K

View Form 4 on SEC.gov

EcoR1 Capital Fund Qualified, L.P.

10 percent owner

Sale

Date

Nov 9

Shares

5,819

Price

$4.15

Value

$24K

View Form 4 on SEC.gov

EcoR1 Capital Fund Qualified, L.P.

10 percent owner

Sale

Date

Nov 10

Shares

5,860

Price

$4.00

Value

$23K

View Form 4 on SEC.gov

EcoR1 Capital Fund Qualified, L.P.

10 percent owner

Sale

Date

Nov 13

Shares

1,083

Price

$3.95

Value

$4K

View Form 4 on SEC.gov

EcoR1 Capital Fund Qualified, L.P.

10 percent owner

Purchase

Date

Oct 1

Shares

4,879

Price

$5.05

Value

$25K

View Form 4 on SEC.gov

Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About ATYR insider trading

ATYR insider trades

aTyr Pharma, Inc. (ATYR) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including SCHIMMEL PAUL (Director), Shukla Sanjay (President and CEO · Director), Broadfoot Jill Marie (CFO). Over the past 12 months, 4 insiders have filed transactions with the SEC. ATYR insiders have been mixed buying and selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For aTyr Pharma, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic
acquisitionOrDisposition field:
A = Acquisition (buy) · D = Disposition (sell)
RSU vesting (M-Exempt) excluded from sentiment
Form 4SEC filing required within 2 business days of any insider transaction
10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot
Open MktDirect purchase or sale on the open market (excludes awards, options)

Frequently asked questions

ATYR insider trading · 5 questions

The insiders of aTyr Pharma, Inc. (ATYR) include executives and directors such as SCHIMMEL PAUL (Director), Shukla Sanjay (President and CEO · Director), Broadfoot Jill Marie (CFO), among others. Over the past 12 months, 4 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

ATYR board member insider tradingwho are ATYR insidersATYR insider rosteraTyr Pharma, Inc. executives insider activity

Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026